(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/002894 A1

(51) International Patent Classification:
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/EP2021/067776

(22) International Filing Date:
29 June 2021 (29.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/705,463	29 June 2020 (29.06.2020)	US
20187409.6	23 July 2020 (23.07.2020)	EP

(71) Applicant: **JANSSEN VACCINES & PREVENTION B.V.** [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL).

(72) Inventors: **CALLENDRET, Benoit, C.,S.**; Archimedesweg 4-6, 2333 CN Leiden (NL). **DE PAEPE, Els**; c/o Janssen Pharmaceutical NV Turnhoutseweg 30, B-2340 Beerse (BE). **COMEAUX, Christy, Ann**; Archimedesweg 4-6, 2333 CN Leiden (NL). **ZAHN, Roland, Christian**; Archimedesweg 4-6, 2333 CN Leiden (NL). **HEIJNEN, Esther, Mathilde, Eugene, Wilhelmus**; Archimedesweg 4-6, 2333 CN Leiden (NL).

(74) Agent: **MANTEN, Annemieke** et al.; Janssen Vaccines & Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION

(57) Abstract: Methods of safely inducing a protective immune response against respiratory syncytial virus (RSV) and methods of preventing infection and/or replication of RSV in human subjects are described. The methods include administering to the subjects (a) an effective amount of an adenoviral vector encoding a recombinant RSV F protein that is stabilized in a pre-fusion conformation, and (b) an effective amount of an RSV F protein that is stabilized in a pre-fusion conformation.

WO 2022/002894 A1